Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-17-017677
Filing Date
2017-08-14
Accepted
2017-08-14 16:49:21
Documents
51
Period of Report
2017-06-30

Document Format Files

Seq Description Document Type Size
1 FATE-10Q-20170630 fate-10q_20170630.htm 10-Q 1274019
2 EX-4.2 fate-ex42_204.htm EX-4.2 89220
3 EX-10.1 fate-ex101_203.htm EX-10.1 53956
4 EX-31.1 fate-ex311_7.htm EX-31.1 9826
5 EX-32.1 fate-ex321_6.htm EX-32.1 4807
  Complete submission text file 0001564590-17-017677.txt   5074706

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT fate-20170630.xml EX-101.INS 955460
7 XBRL TAXONOMY EXTENSION SCHEMA fate-20170630.xsd EX-101.SCH 42681
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE fate-20170630_cal.xml EX-101.CAL 39875
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE fate-20170630_def.xml EX-101.DEF 190677
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE fate-20170630_lab.xml EX-101.LAB 339476
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fate-20170630_pre.xml EX-101.PRE 273880
Mailing Address 3535 GENERAL ATOMICS COURT SUITE 200 SAN DIEGO CA 92121
Business Address 3535 GENERAL ATOMICS COURT SUITE 200 SAN DIEGO CA 92121 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36076 | Film No.: 171031074
SIC: 2836 Biological Products, (No Diagnostic Substances)